Company Overview and News
Iteris, Inc. (ITI) was a big mover last session, as the company saw its shares rise over 8% on the day.
While aggressive investors love biotechnology, and the returns over the years for the top stocks have been outstanding, 2016 could be a wild-card, as the election cycle is going to keep drug pricing and health care costs front and center. Politicians looking for votes like nothing better than to find a scapegoat for bellicose populist rhetoric.
valleyforge_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY Investment Company Act file number: 811-58431 Name of Registrant: Vanguard Valley Forge Funds Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482 Name and address of agent for service: Heidi Stam, Esquire P.
index_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY Investment Company Act file number: 811-02652 Name of Registrant: Vanguard Index Funds Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482 Name and address of agent for service: Heidi Stam, Esquire P.
Iteris, Inc. (NYSEMKT:ITI) Q2 2016 Earnings Conference Call November 10, 2015, 4:30 pm ET Executives Joe Bergera - President & CEO Andy Schmidt - CFO Analysts Jeff Van Sinderen - B. Riley Presenta
The company's traffic technology segment generates $5 million per year in cash.Connected and autonomous vehicles create future opportunity.ClearAg's is facing stiff competition, in a new industry, wit
Valuable Core Business: A co-leader at worst in the camera based traffic control market. Flir Systems paid $46m for co-leader Traficon in December 2012. Enjoys a stable pure profit royalty stream of $
Iteris Inc. (NYSEMKT:ITI) Q1 2015 Earnings Conference Call October 16, 2014 4:30 PM ET Executives Abbas Mohaddes – President and Chief Executive Officer Craig Christensen – Chief Financial Officer (I
Top Idea: Layne Christensen by BuyTheDip SellTheRip: Long / Micro-Cap / Heavy Construction / Contrarian / Lagging Market Sentiment / Sum of the Parts / 100% Upside Top Idea: Hutchinson Technology by T
Iteris, Inc. (NYSEMKT:ITI) Q4 2014 Earnings Conference Call September 3, 2014 4:30 PM ET Executives Abbas Mohaddes – President and Chief Executive Officer Craig Christensen – Chief Financial Officer
14h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
14h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...